4-[bis[(4-methoxyphenyl)methyl]amino]-1-(1,1,1-trifluoropropan-2-yl)-3H-imidazo[4,5-c]pyridin-2-one
C25H25F3N4O3 — CID 163288210
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[bis[(4-methoxyphenyl)methyl]amino]-1-(1,1,1-trifluoropropan-2-yl)-3H-imidazo[4,5-c]pyridin-2-one
4-[bis[(4-methoxyphenyl)methyl]amino]-1-(1,1,1-trifluoropropan-2-yl)-3H-imidazo[4,5-c]pyridin-2-one (PubChem CID 163288210) has the molecular formula C25H25F3N4O3 and a molecular weight of 486.49 g/mol. Its IUPAC name is 4-[bis[(4-methoxyphenyl)methyl]amino]-1-(1,1,1-trifluoropropan-2-yl)-3H-imidazo[4,5-c]pyridin-2-one.
Molecular Properties
| Compound Name | 4-[bis[(4-methoxyphenyl)methyl]amino]-1-(1,1,1-trifluoropropan-2-yl)-3H-imidazo[4,5-c]pyridin-2-one |
|---|---|
| PubChem CID | 163288210 |
| Molecular Formula | C25H25F3N4O3 |
| Molecular Weight | 486.49 g/mol |
| Exact Mass | 486.19 |
| IUPAC Name | 4-[bis[(4-methoxyphenyl)methyl]amino]-1-(1,1,1-trifluoropropan-2-yl)-3H-imidazo[4,5-c]pyridin-2-one |
| SMILES | COc1ccc(CN(Cc2ccc(OC)cc2)c2nccc3c2[nH]c(=O)n3C(C)C(F)(F)F)cc1 |
| InChI | InChI=1S/C25H25F3N4O3/c1-16(25(26,27)28)32-21-12-13-29-23(22(21)30-24(32)33)31(14-17-4-8-19(34-2)9-5-17)15-18-6-10-20(35-3)11-7-18/h4-13,16H,14-15H2,1-3H3,(H,30,33) |
| InChIKey | XQXNUVKTIOOYNU-UHFFFAOYSA-N |
| XLogP | 5.07 |
| TPSA | 72.38 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 486.49 |
| LogP ≤ 5 | 5.07 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163288210 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.